Medications for Rheumatoid Arthritis
Start methotrexate (MTX) 7.5-10 mg orally weekly, rapidly escalating to 20-25 mg weekly within 4-8 weeks, combined with short-term low-dose glucocorticoids (prednisone 5-7.5 mg/day or single intramuscular methylprednisolone 80-160 mg) tapered within 3 months. This represents the gold standard first-line approach for newly diagnosed RA with moderate-to-high disease activity 1, 2, 3.
Phase I: Initial Treatment Strategy
First-Line Therapy
- Methotrexate is the anchor DMARD and should be part of the first treatment strategy for all patients with active RA unless contraindicated 1, 4
- Optimal dosing: 25-30 mg weekly with folate supplementation; maximum effect requires 4-6 months 5
- Add short-term glucocorticoids (≤3 months) as bridging therapy until MTX exhibits efficacy 1, 2
If MTX is Contraindicated or Not Tolerated
- Use leflunomide (20 mg/day) or sulfasalazine (2-4 g/day) as alternative first-line csDMARDs 1, 4
- Hydroxychloroquine has limited efficacy and is reserved for mild RA or low disease activity 1
Monitoring and Treatment Targets
- Assess response at 3 months: If no improvement, adjust therapy immediately 1, 2
- Target achievement by 6 months: Clinical remission (CDAI ≤2.8) or at least low disease activity 1
- Monitor every 1-3 months during active disease 1
Phase II: Escalation for Inadequate Response
With Poor Prognostic Factors Present
Poor prognostic factors include: RF/ACPA positivity (especially high levels), high disease activity, early erosions, or failure of 2 csDMARDs 1, 2
Add a biological DMARD to MTX 1, 2, 3:
- TNF inhibitors: adalimumab, certolizumab pegol, etanercept, golimumab, infliximab (including biosimilars)
- IL-6 receptor inhibitors: tocilizumab, sarilumab
- T-cell costimulation inhibitor: abatacept
- B-cell depleting agent: rituximab (particularly with history of lymphoma or demyelinating disease)
JAK inhibitors may be considered (baricitinib, tofacitinib, upadacitinib, filgotinib) but only after careful risk assessment for major cardiovascular events (MACEs), malignancies, and thromboembolic events 2, 3
Without Poor Prognostic Factors
- Change to or add another csDMARD (leflunomide, sulfasalazine, or combinations) 1
- Consider triple therapy: MTX + sulfasalazine + hydroxychloroquine 1
Phase III: Switching After bDMARD/JAKi Failure
If first bDMARD or JAKi fails, switch to another bDMARD (same or different class) or JAKi 1, 2, 3:
- After TNF inhibitor failure: can use another TNF inhibitor OR switch to different mechanism (abatacept, rituximab, IL-6 inhibitor, JAKi)
- Combination with csDMARD (preferably MTX) is recommended for all bDMARDs 1
- IL-6 inhibitors and JAKi have advantages when csDMARDs cannot be used as comedication 1
Critical Safety Considerations
JAK Inhibitor Warnings
Exercise extreme caution with JAK inhibitors in patients with:
- Age ≥65 years
- History of cardiovascular disease or risk factors for MACEs
- Current or past malignancy
- Risk factors for thromboembolic events 2, 3
Glucocorticoid Use
- Short-term use (<3 months) is acceptable as bridging therapy 1, 2
- Longer-term use (≥3 months) is strongly discouraged due to cumulative toxicity 4
- Failure to maintain target after GC taper = treatment failure requiring bDMARD/JAKi addition 1
Tapering in Sustained Remission
Once sustained remission achieved (≥6 months after GC taper) 1, 2:
- Consider tapering bDMARDs/JAKi first (dose reduction or interval prolongation) if combined with csDMARD
- Do not stop bDMARDs/JAKi completely - high flare rates occur; most can recapture response upon reinstitution 1
- Only after prolonged remission, cautiously consider csDMARD dose reduction as shared decision with patient 1
Common Pitfalls to Avoid
- Insufficient MTX dosing: Must reach 25-30 mg weekly and maintain for ≥8 weeks before declaring failure 5
- Premature treatment changes: Allow 3 months minimum for improvement, 6 months for target achievement 1
- Monotherapy with bDMARDs: Always combine with csDMARD (especially MTX) unless contraindicated 1
- Prolonged glucocorticoid use: Taper aggressively within 3 months 1, 2
- Stopping DMARDs in remission: Taper cautiously; complete cessation leads to high flare rates 1